Please ensure Javascript is enabled for purposes of website accessibility
Merck Asks FDA to Authorize Promising Anti-COVID Pill
gvw_ap_news
By Associated Press
Published 2 years ago on
October 11, 2021

Share

WASHINGTON — Drugmaker Merck asked U.S. regulators Monday to authorize its pill for treating COVID-19 in what would add an entirely new and easy-to-use weapon to the world’s arsenal against the pandemic.

If cleared by the Food and Drug Administration — a decision that could come in a matter of weeks — it would be the first pill shown to treat the illness. All other FDA-backed treatments against COVID-19 require an IV or injection.

An antiviral pill that people could take at home to reduce their symptoms and speed recovery could prove groundbreaking, easing the crushing caseload on U.S. hospitals and helping to curb outbreaks in poorer countries with weak health care systems. It would also bolster the two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.

The FDA will scrutinize company data on the safety and effectiveness of the drug, molnupiravir, before rendering a decision.

Merck Asks FDA to Approve Pill for Emergency Use

Merck and its partner Ridgeback Biotherapeutic said they specifically asked the agency to grant emergency use for adults with mild-to-moderate COVID-19 who are at risk for severe disease or hospitalization. That is roughly the way COVID-19 infusion drugs are used.

“The value here is that it’s a pill so you don’t have to deal with the infusion centers and all the factors around that,” said Dr. Nicholas Kartsonis, a senior vice president with Merck’s infectious disease unit. “I think it’s a very powerful tool to add to the toolbox.”

The company reported earlier this month that the pill cut hospitalizations and deaths by half among patients with early symptoms of COVID-19. The results were so strong that independent medical experts monitoring the trial recommended stopping it early.

Side effects were similar between patients who got the drug and those in a testing group who received a dummy pill. But Merck has not publicly detailed the types of problems reported, which will be a key part of the FDA’s review.

Health Officials Still Pushing for Vaccinations

Top U.S. health officials continue to push vaccinations as the best way to protect against COVID-19.

“It’s much, much better to prevent yourself from getting infected than to have to treat an infection,” Dr. Anthony Fauci said while discussing Merck’s drug last week.

Still, some 68 million eligible Americans remain unvaccinated, underscoring the need for effective drugs to control future waves of infection.

The prospect of a COVID-19 pill comes amid other encouraging signs: New cases per day in the U.S. have dropped below 100,000 on average for the first time in over two months, and deaths are running at about 1,700 a day, down from more than 2,000 three weeks ago.

Also, the average number of vaccinations dispensed per day has climbed past 1 million, an increase of more than 50% over the past two weeks, driven by the introduction of booster shots and workplace vaccine requirements.

Still, heath authorities are bracing for another possible surge as cold weather drives more people indoors.

Pill to Cost Roughly $700 for Each Treatment

Since the beginning of the pandemic, health experts have stressed the need for a convenient pill. The goal is for something similar to Tamiflu, the 20-year-old flu medication that shortens the illness by a day or two and blunts the severity of symptoms like fever, cough and stuffy nose.

Three FDA-authorized antibody drugs have proved highly effective at reducing COVID-19 deaths, but they are expensive, hard to produce and require specialty equipment and health professionals to deliver.

Assuming FDA authorization, the U.S. government has agreed to buy enough of the pills to treat 1.7 million people, at a price of roughly $700 for each course of treatment. That’s less than half the price of the antibody drugs purchased by the U.S. government — over $2,000 per infusion — but still more expensive than many antiviral pills for other conditions.

Merck’s Kartsonis said in an interview that the $700 figure does not represent the final price for the medication.

“We set that price before we had any data, so that’s just one contract,” Kartsonis said. “Obviously we’re going to be responsible about this and make this drug as accessible to as many people around the world as we can.”

Other Companies Also Studying Similar Drugs

Kenilworth, New Jersey-based Merck has said it is in purchase talks with governments around the world and will use a sliding price scale based on each country’s economic means. Also, the company has signed licensing deals with several Indian generic drugmakers to produce low-cost versions of the drug for lower-income countries.

Several other companies, including Pfizer and Roche, are studying similar drugs and are expected to report results in the coming weeks and months. AstraZeneca is also seeking FDA authorization for a long-acting antibody drug intended to provide months of protection for patients who have immune-system disorders and do not adequately respond to vaccination.

Some experts predict various COVID-19 therapies eventually will be prescribed in combination to better protect against the worst effects of the virus.

RELATED TOPICS:

DON'T MISS

Supreme Court Appears Likely to Preserve Access to Abortion Medication Mifepristone

DON'T MISS

California Wants to Pay Doctors More Money to See Medicaid Patients

DON'T MISS

While Valley Children’s Executives Earn Millions, Community Benefits Lag

DON'T MISS

US Surgeons Have Transplanted a Pig Kidney Into a Patient

DON'T MISS

US Drops in World Happiness Rankings as Those Under 30 Report Declining Well-Being

DON'T MISS

Valley Children’s Sends Third Party to KMJ to Explain Suntrapak’s Salary, Benefits

DON'T MISS

Top Former US Generals Say Failures of Biden Administration in Planning Drove Chaotic Fall of Kabul

DON'T MISS

10 Surprising Foods That Boost Your Immunity

DON'T MISS

US Defense Chief Vows Continued Aid to Ukraine, Even as Congress Is Stalled on Funding Bill

DON'T MISS

Records Show That Valley Children’s Leader Suntrapak’s Pay Exceeds $5 Million

No data was found

Trump Criticizes Judge and His Daughter After Gag Order in Hush-Money Case

13 hours ago

CA Insurance Market ‘in Chaos,’ Says Former Insurance Commissioner. Can Lara Fix It?

14 hours ago

Stock Market Today: S&P 500 Sets a Record After Wall Streets Breaks Out of Its Lull

14 hours ago

House Speaker Mike Johnson Headed to Fresno on April 4

14 hours ago

Bredefeld, Smittcamp Debate the Salary of Valley Children’s CEO

15 hours ago

CA’s Liberal Government Has a Long History of Caving to Special Interests

15 hours ago

Corrupt Process? Bullard, Edison Parents Blast Handling of Superintendent Search

15 hours ago

Police Had About 90 Seconds to Stop Traffic Before Baltimore Bridge Fell. 6 Workers Are Feared Dead

16 hours ago

NBC Has Cut Ties With Former RNC Head Ronna McDaniel After Employee Objections, Some on the Air

17 hours ago

Here Are Some Numbers That Will Help You Get Your March Madness Fix for the Sweet 16

17 hours ago

Ukrainian Navy Says a Third of Russian Warships in the Black Sea Have Been Destroyed or Disabled

KYIV, Ukraine — Ukraine has sunk or disabled a third of all Russian warships in the Black Sea in just over two years of war, the navy spokes...

7 hours ago

7 hours ago

Ukrainian Navy Says a Third of Russian Warships in the Black Sea Have Been Destroyed or Disabled

Composite image of President Trump and Devin Nunes
12 hours ago

Wired Wednesday: How Going to Work for Trump Turned Devin Nunes Into a Millionaire

12 hours ago

Former Sen. Joe Lieberman, Democrats’ VP Pick in 2000, Dead at 82

13 hours ago

Trump Criticizes Judge and His Daughter After Gag Order in Hush-Money Case

14 hours ago

CA Insurance Market ‘in Chaos,’ Says Former Insurance Commissioner. Can Lara Fix It?

14 hours ago

Stock Market Today: S&P 500 Sets a Record After Wall Streets Breaks Out of Its Lull

14 hours ago

House Speaker Mike Johnson Headed to Fresno on April 4

15 hours ago

Bredefeld, Smittcamp Debate the Salary of Valley Children’s CEO

MENU

CONNECT WITH US

Search

Send this to a friend